Saturday bloom on CVS Health Corporation (NYSE:CVS) [Trend Analysis], stock slightly up about 0.91% in early session as its gaining volume of 6.7 Million. CVS Pharmacy, the retail division of CVS Health (CVS), reported that it will offer an extensive array of in-store and online resources to assist senior patients in determining the best 2017 Medicare Part D prescription drug plan during the Yearly Enrollment period. Open enrollment for Medicare Part D starts October 15 and ends December 7, 2016.
Convenient access to information about local and national Medicare Part D plans will be accessible to patients – in both English and Spanish – at all 9,600 CVS Pharmacy locations nationwide. In addition, over 11,000 informational events will be held in select CVS Pharmacy stores across the country during the Open Enrollment period where representatives from local health plans will provide Medicare Part D information to eligible patients and answer any questions they may have.
CVS Pharmacy’s online Health Insurance Information Center, www.cvs.com/Medicare, offers information on accessible Medicare Part D plans. The website features information that assists seniors find a plan in their community and guides them on how to enroll. For seniors evaluating Medicare Part D plans, they can enter their prescription information and zip code to compare plans accessible to them. Patients can also find a listing of store informational insurance events in their community.
The stock showed weekly upbeat performance of 2.78%, which maintained for the month at -1.50%. Samely, the positive performance for the quarter recorded as -7.93% and for the year was -11.86%, while the YTD performance remained at -7.99%. CVS has Average True Range for 14 days of 1.17.
Mylan N.V. (NASDAQ:MYL) [Trend Analysis] pretends to be active mover, stock plunged about -3.67% to traded at $36.49. Glancy Prongay & Murray LLP reported an examination on behalf of Mylan N.V. (NASDAQ: MYL) investors concerning the Firm and its officers’ possible infringement of federal securities laws.
Mylan, together with its subsidiaries, develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals worldwide. Specifically, the examination concerns a letter issued on October 5, 2016 from the Centers for Medicare and Medicaid Services (“CMS”) asserting that Mylan had overcharged the U.S. Medicaid health program for the Firm’s EpiPen shot, despite being told that Mylan needed to provide larger discounts under the law. The CMS letter stated that from 2011 to 2015, the U.S. Medicaid health program spent about $797 million on EpiPens, comprising rebates of roughly 13%, rather than the discount of 23.1% that the U.S. should have attained. The letter claimed that the government had “expressly told Mylan that the [EpiPen] product is incorrectly classified.”
The liquidity measure in recent quarter results of the firm was recorded 3.20 as current ratio, on the other side the debt to equity ratio was 1.31, and long-term debt to equity ratio remained 1.31. The Firm has gross margin of 45.30% and profit margin was positive 8.10% in trailing twelve months. (Read Recent [Free Analytic] Facts on NASDAQ:MYL and Be Updated)
For recent Market Updates Subscribes Here